Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9377097 | 0.81 | APOBEC3A (0.38) | HTTTSHRMEN1NPC1RAB9A | |
| SCHEMBL1625851 | 0.80 | LMNA (0.44) | HTTTSHRL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL9864828 | 0.80 | NPC1 (0.48) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19858926 | 0.78 | SMN1; SMN2 (0.51) | HTTTSHRL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL3396184 | 0.76 | TSHR (0.58) | HTTTSHRL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL29006929 | 0.76 | GAA (0.46) | L3MBTL1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19858912 | 0.76 | NPC1 (0.51) | HTTL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL11213475 | 0.76 | CYP1A2 (0.53) | HTTTSHRL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL9377052 | 0.74 | NPC1 (0.40) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL16429126 | 0.73 | PTGS2 (0.44) | HTTSMN1; SMN2CYP1A2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20180340174-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | NANOCORE APS (DK) | 2018-11-29 | — | — | US | disclosed |
| US-10112929-B2 | Lactams as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3218479-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | Nanocore ApS (DK) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016074683-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | LUNDORF PEDERSEN MATERIALS APS (DK) | 2016-05-19 | — | — | WO | disclosed |
| CN-103221046-A | Piperidinyl-substituted lactams as gpr119 modulators | ARRAY BIOPHARMA INC | 2013-07-24 | — | — | CN | disclosed |
| CN-103080101-A | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC | 2013-05-01 | — | — | CN | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| EP-1200435-B1 | PURINE DERIVATIVES INHIBITORS OF TYROSINE PROTEIN KINASE SYK | NOVARTIS AG (CH) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | HTT 3428/4885TSHR 4815/4885L3MBTL1 1939/4885 |
| US-10112929-B2 | Lactams as inhibitors of rock | MYLK, ROCK1, RHOA | HTT 4709/4885TSHR 3341/4885L3MBTL1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.